# Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization

Study · id `cardio:ct-nct03072121` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03072121](<https://clinicaltrials.gov/study/NCT03072121>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03072121

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 440 participants.

## Technical summary

Registry record NCT03072121. Randomized; double masking; primary purpose treatment. Start 2017-06 (anticipated); primary completion 2018-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 440 participants (planned count; ClinicalTrials.gov record NCT03072121, source copy `cardio:ctgov-nct03072121-2017-04-04`, retrieved 2026-10-26)
- Planned start: 2017-06 (anticipated) (ClinicalTrials.gov record NCT03072121, source copy `cardio:ctgov-nct03072121-2017-04-04`, retrieved 2026-10-26)
- Primary completion: 2018-12 (anticipated) (ClinicalTrials.gov record NCT03072121, source copy `cardio:ctgov-nct03072121-2017-04-04`, retrieved 2026-10-26)
- Completion: 2019-02 (anticipated) (ClinicalTrials.gov record NCT03072121, source copy `cardio:ctgov-nct03072121-2017-04-04`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03072121-2017-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization
- Condition: Coronary Artery Disease(CAD)
- Intervention (Drug): Shexiang Baoxin pill
- Intervention (Drug): SBP placebo
- Intervention (Drug): Aspirin Enteric-coated Tablets
- Intervention (Drug): Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
- Intervention (Drug): Atorvastatin Calcium
- Intervention (Drug): Isosorbide Mononitrate Tab 20 MG
- Intervention (Drug): Metoprolol Tartrate Tab 25 MG
- Intervention (Drug): Trimetazidine Dihydrochloride Tablets
- Lead sponsor: Jun Li
- Lead sponsor class: OTHER
- Collaborator: Shanghai Hutchison Pharmaceuticals Limited
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Jun Li (`cardio:org-jun-li`)
- Registry lists this organization as a collaborator: Shanghai Hutchison Pharmaceuticals Limited (`cardio:org-shanghai-hutchison-pharmaceuticals-limited`)

## Provenance

Content hash: 0ab60d2d2e32bf9447f354ae7f85a619c75387bf36d6ab9e609ccc40f01a898c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
